Don’t let patients with
TARGETABLE MUTATIONS
get lost in the crowd

Detecting oncogenic drivers at diagnosis is an urgent need in mNSCLC

mNSCLC calls for broad molecular profiling1
Patients with oncogenic drivers METex14 or BRAF  V600E may face a poor prognosis2-4
Multidisciplinary collaboration is critical to an accurate and timely diagnosis1,5,6

BRAF, v-raf murine sarcoma viral oncogene homolog B1; MET, mesenchymal-epithelial transition; METex14, MET exon 14 skipping; mNSCLC, metastatic non-small cell lung cancer.

References

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.7.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed October 29, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Yeung SF, Tong JHM, Law PPW, et al. J Thorac Oncol. 2015;10(9):1292-1300. 
  3. Tong JH, Yeung SF, Chan AWH, et al. Clin Cancer Res. 2016;22(12):3048-3056.
  4. Marchetti A, Felicioni L, Malatesta S, et al. J Clin Oncol. 2011;29(26):3574-3579.
  5. Ofiara LM, Navasakulpong A, Beaudoin S, Gonzalez AV. Front Oncol. 2014;4:253. doi: 10.3389/fonc.2014.00253.
  6. Conde E, Angulo B, Izquierdo E, et al. Clin Transl Oncol. 2013;15(7):503-508.

This is a global website and is intended for health care professionals. The information on this site is intended for educational purposes only and is not country-specific.

 

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2021 Novartis AG. All rights reserved.

10/21     130870